These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 2748524)

  • 1. In vitro release profiles of clonidine transdermal therapeutic systems and scopolamine transdermal patches.
    Shah VP; Tymes NW; Skelly JP
    Pharm Res; 1989 Apr; 6(4):346-51. PubMed ID: 2748524
    [No Abstract]   [Full Text] [Related]  

  • 2. In vitro and in vivo characterization of a newly developed clonidine transdermal patch for treatment of attention deficit hyperactivity disorder in children.
    Ke GM; Wang L; Xue HY; Lu WL; Zhang X; Zhang Q; Guo HY
    Biol Pharm Bull; 2005 Feb; 28(2):305-10. PubMed ID: 15684489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro release profile of estradiol transdermal therapeutic systems.
    Tymes NW; Shah VP; Skelly JP
    J Pharm Sci; 1990 Jul; 79(7):601-2. PubMed ID: 2398467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of mathematical models describing drug release from estradiol transdermal systems.
    Costa P; Sousa Lobo JM
    Drug Dev Ind Pharm; 2003 Jan; 29(1):89-97. PubMed ID: 12602496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of contact dermatitis associated with transdermal therapeutic systems.
    Holdiness MR
    Contact Dermatitis; 1989 Jan; 20(1):3-9. PubMed ID: 2492460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rate and extent of absorption of clonidine from a transdermal therapeutic system.
    Toon S; Hopkins KJ; Aarons L; Rowland M
    J Pharm Pharmacol; 1989 Jan; 41(1):17-21. PubMed ID: 2565958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fabrication and characterization of matrix type transdermal patches loaded with tizanidine hydrochloride: potential sustained release delivery system.
    Shahid N; Siddique MI; Razzaq Z; Katas H; Waqas MK; Rahman KU
    Drug Dev Ind Pharm; 2018 Dec; 44(12):2061-2070. PubMed ID: 30081679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioequivalence and adhesion evaluation of transdermal clonidine following a change in excipient supplier.
    Ehrlich J; Beck B; Thiedmann R; Marzin K; MacGregor T
    Int J Clin Pharmacol Ther; 2016 Oct; 54(10):816-24. PubMed ID: 27390050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Transdermal administration of drugs].
    Merkus FW
    Ned Tijdschr Geneeskd; 1986 Dec; 130(51):2291-2. PubMed ID: 3821946
    [No Abstract]   [Full Text] [Related]  

  • 10. Adverse dermatologic reactions to transdermal drug delivery systems.
    Hogan DJ; Maibach HI
    J Am Acad Dermatol; 1990 May; 22(5 Pt 1):811-4. PubMed ID: 2112162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antihypertensive effects of a new transdermal delivery system for clonidine (M-5041T) in spontaneously hypertensive rats.
    Ishii R; Naruse T; Tagawa T; Yamahata T; Dote S; Hamada K; Ishida T; Funabiki K; Namba K
    Arch Int Pharmacodyn Ther; 1994; 327(3):294-308. PubMed ID: 7848013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The promise of transdermal drug delivery.
    Nimmo WS
    Br J Anaesth; 1990 Jan; 64(1):7-10. PubMed ID: 2105738
    [No Abstract]   [Full Text] [Related]  

  • 13. Transdermal clonidine. A preliminary review of its pharmacodynamic properties and therapeutic efficacy.
    Langley MS; Heel RC
    Drugs; 1988 Feb; 35(2):123-42. PubMed ID: 3281820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transdermal drug delivery: a review of pharmaceutics, pharmacokinetics, and pharmacodynamics.
    Moore L; Chien YW
    Crit Rev Ther Drug Carrier Syst; 1988; 4(4):285-349. PubMed ID: 3133121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic adherence in the elderly: transdermal clonidine compared to oral verapamil for hypertension.
    Burris JF; Papademetriou V; Wallin JD; Cook ME; Weidler DJ
    Am J Med; 1991 Jul; 91(1A):22S-28S. PubMed ID: 1867225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose linearity of clonidine after transdermal application.
    Wallenstein G; Gladigau V
    Clin Auton Res; 1993 Dec; 3(6):369-72. PubMed ID: 8193523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transdermal delivery of drugs.
    Brown L; Langer R
    Annu Rev Med; 1988; 39():221-9. PubMed ID: 3130771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influences of bathing and hot weather on the pharmacokinetics of a new transdermal clonidine, M-5041T.
    Fujimura A; Sasaki M; Harada K; Kumagai Y; Ohashi K; Ebihara A
    J Clin Pharmacol; 1996 Oct; 36(10):892-6. PubMed ID: 8930775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy of current transdermal drug delivery systems: a retrospective evaluation.
    Berba J; Banakar U
    Am Pharm; 1990 Nov; NS30(11):33-7, 40-1. PubMed ID: 2124411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of application site of a new transdermal clonidine, M-5041T, on its pharmacokinetics and pharmacodynamics in healthy subjects.
    Ebihara A; Fujimura A; Ohashi K; Shiga T; Kumagai Y; Nakashima H; Kotegawa T
    J Clin Pharmacol; 1993 Dec; 33(12):1188-91. PubMed ID: 8126253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.